The tuberous sclerosis complex (TSC) pathway and mechanism of size control

Christopher J Potter, L. G. Pedraza, H. Huang, T. Xu

Research output: Contribution to journalArticle

Abstract

We have identified three groups of growth-constraint genes using mosaic genetic screens in Drosophila melanogaster, including PTEN (phosphatase and tensin homologue deleted on chromosome 10), and the tuberous sclerosis complex (TSC) genes, Tsc1 and Tsc2. our studies show that all three groups of genes participate in mechanisms that regulate organ and organism size in animals. We propose that mechanisms of organ size control are critical targets for diseases, such as tumorigenesis, which require an increase in tissue size and total mass, and for evolutionary events that alter the size of organisms. Using genetic and biochemical methods, we have shown that Tsc1 and Tsc2 function in the insulin/phosphoinositide 3-kinase (PI3K)/Akt pathway. We have shown that Akt regulates the Tsc1-Tsc2 complex by directly phosphorylating Tsc2. We have shown further that S6 kinase (S6K) is a downstream component of the PI3K/Akt/TSC pathway and reduction of S6K activity can block TSC defects. Recent studies from many laboratories have now confirmed our findings in mice, rats and human patients, and have shown that drugs that antagonize S6K activities, such as rapamycin, diminish turnouts in TSC-deficient mice and rats. Clinical trials based on these findings have begun. Given that other components of the pathway, such as PTEN, are also mutated in a large number of cancer patients and that these components regulate intracellular insulin signalling, therapeutics based on the knowledge of the pathway could have effects beyond the TSC patient population.

Original languageEnglish (US)
Pages (from-to)584-586
Number of pages3
JournalBiochemical Society Transactions
Volume31
Issue number3
DOIs
StatePublished - Jun 2003
Externally publishedYes

Fingerprint

Ribosomal Protein S6 Kinases
Tuberous Sclerosis
Genes
Phosphatidylinositols
Rats
Phosphotransferases
PTEN Phosphohydrolase
1-Phosphatidylinositol 4-Kinase
Organ Size
Insulin
Sirolimus
Chromosomes
Animals
Chromosomes, Human, Pair 10
Tissue
Defects
Drosophila melanogaster
Molecular Biology
Carcinogenesis
Pharmaceutical Preparations

Keywords

  • Drosophila genetics
  • Phosphoinositide 3-kinase (PI3K)/PTEN/Akt/tuberous sclerosis complex (TSC) pathway
  • Size-control mechanisms
  • Tuberous sclerosis gene function
  • Tumourigenesis

ASJC Scopus subject areas

  • Biochemistry

Cite this

The tuberous sclerosis complex (TSC) pathway and mechanism of size control. / Potter, Christopher J; Pedraza, L. G.; Huang, H.; Xu, T.

In: Biochemical Society Transactions, Vol. 31, No. 3, 06.2003, p. 584-586.

Research output: Contribution to journalArticle

@article{dc0ffa69c54240c28ec7091fb106f583,
title = "The tuberous sclerosis complex (TSC) pathway and mechanism of size control",
abstract = "We have identified three groups of growth-constraint genes using mosaic genetic screens in Drosophila melanogaster, including PTEN (phosphatase and tensin homologue deleted on chromosome 10), and the tuberous sclerosis complex (TSC) genes, Tsc1 and Tsc2. our studies show that all three groups of genes participate in mechanisms that regulate organ and organism size in animals. We propose that mechanisms of organ size control are critical targets for diseases, such as tumorigenesis, which require an increase in tissue size and total mass, and for evolutionary events that alter the size of organisms. Using genetic and biochemical methods, we have shown that Tsc1 and Tsc2 function in the insulin/phosphoinositide 3-kinase (PI3K)/Akt pathway. We have shown that Akt regulates the Tsc1-Tsc2 complex by directly phosphorylating Tsc2. We have shown further that S6 kinase (S6K) is a downstream component of the PI3K/Akt/TSC pathway and reduction of S6K activity can block TSC defects. Recent studies from many laboratories have now confirmed our findings in mice, rats and human patients, and have shown that drugs that antagonize S6K activities, such as rapamycin, diminish turnouts in TSC-deficient mice and rats. Clinical trials based on these findings have begun. Given that other components of the pathway, such as PTEN, are also mutated in a large number of cancer patients and that these components regulate intracellular insulin signalling, therapeutics based on the knowledge of the pathway could have effects beyond the TSC patient population.",
keywords = "Drosophila genetics, Phosphoinositide 3-kinase (PI3K)/PTEN/Akt/tuberous sclerosis complex (TSC) pathway, Size-control mechanisms, Tuberous sclerosis gene function, Tumourigenesis",
author = "Potter, {Christopher J} and Pedraza, {L. G.} and H. Huang and T. Xu",
year = "2003",
month = "6",
doi = "10.1042/BST0310584",
language = "English (US)",
volume = "31",
pages = "584--586",
journal = "Biochemical Society Transactions",
issn = "0300-5127",
publisher = "Portland Press Ltd.",
number = "3",

}

TY - JOUR

T1 - The tuberous sclerosis complex (TSC) pathway and mechanism of size control

AU - Potter, Christopher J

AU - Pedraza, L. G.

AU - Huang, H.

AU - Xu, T.

PY - 2003/6

Y1 - 2003/6

N2 - We have identified three groups of growth-constraint genes using mosaic genetic screens in Drosophila melanogaster, including PTEN (phosphatase and tensin homologue deleted on chromosome 10), and the tuberous sclerosis complex (TSC) genes, Tsc1 and Tsc2. our studies show that all three groups of genes participate in mechanisms that regulate organ and organism size in animals. We propose that mechanisms of organ size control are critical targets for diseases, such as tumorigenesis, which require an increase in tissue size and total mass, and for evolutionary events that alter the size of organisms. Using genetic and biochemical methods, we have shown that Tsc1 and Tsc2 function in the insulin/phosphoinositide 3-kinase (PI3K)/Akt pathway. We have shown that Akt regulates the Tsc1-Tsc2 complex by directly phosphorylating Tsc2. We have shown further that S6 kinase (S6K) is a downstream component of the PI3K/Akt/TSC pathway and reduction of S6K activity can block TSC defects. Recent studies from many laboratories have now confirmed our findings in mice, rats and human patients, and have shown that drugs that antagonize S6K activities, such as rapamycin, diminish turnouts in TSC-deficient mice and rats. Clinical trials based on these findings have begun. Given that other components of the pathway, such as PTEN, are also mutated in a large number of cancer patients and that these components regulate intracellular insulin signalling, therapeutics based on the knowledge of the pathway could have effects beyond the TSC patient population.

AB - We have identified three groups of growth-constraint genes using mosaic genetic screens in Drosophila melanogaster, including PTEN (phosphatase and tensin homologue deleted on chromosome 10), and the tuberous sclerosis complex (TSC) genes, Tsc1 and Tsc2. our studies show that all three groups of genes participate in mechanisms that regulate organ and organism size in animals. We propose that mechanisms of organ size control are critical targets for diseases, such as tumorigenesis, which require an increase in tissue size and total mass, and for evolutionary events that alter the size of organisms. Using genetic and biochemical methods, we have shown that Tsc1 and Tsc2 function in the insulin/phosphoinositide 3-kinase (PI3K)/Akt pathway. We have shown that Akt regulates the Tsc1-Tsc2 complex by directly phosphorylating Tsc2. We have shown further that S6 kinase (S6K) is a downstream component of the PI3K/Akt/TSC pathway and reduction of S6K activity can block TSC defects. Recent studies from many laboratories have now confirmed our findings in mice, rats and human patients, and have shown that drugs that antagonize S6K activities, such as rapamycin, diminish turnouts in TSC-deficient mice and rats. Clinical trials based on these findings have begun. Given that other components of the pathway, such as PTEN, are also mutated in a large number of cancer patients and that these components regulate intracellular insulin signalling, therapeutics based on the knowledge of the pathway could have effects beyond the TSC patient population.

KW - Drosophila genetics

KW - Phosphoinositide 3-kinase (PI3K)/PTEN/Akt/tuberous sclerosis complex (TSC) pathway

KW - Size-control mechanisms

KW - Tuberous sclerosis gene function

KW - Tumourigenesis

UR - http://www.scopus.com/inward/record.url?scp=0037864535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037864535&partnerID=8YFLogxK

U2 - 10.1042/BST0310584

DO - 10.1042/BST0310584

M3 - Article

VL - 31

SP - 584

EP - 586

JO - Biochemical Society Transactions

JF - Biochemical Society Transactions

SN - 0300-5127

IS - 3

ER -